Schering-Plough Bridion user fee goal extended

The goal date for FDA action on Schering-Plough's Bridion (sugammadex) NDA is postponed to the third quarter of 2008 "to allow FDA time to review the clinical trial report for the hypersensitivity study that was submitted with the 120-day safety update," Schering-Plough reports March 17. The data, which was submitted shortly before the March 11 meeting of FDA's Advisory Committee on...